TP53 and lung cancer: A recent study combined phage-mediated cancer therapy with clustered, regularly interspaced, short palindrome repeats (CRISPR)/Cas9 genome editing technology and reported the effective co-delivery of CRISPR/Cas9 and a functional p53 gene to target the mutant TP53 gene in human lung cancer [228].